Connected drug delivery products (devices with attached / incorporated capability that includes connectivity to wider digital services) continue to be a driving force in medical devices.
In this whitepaper, Max Middleton explores the key elements that pharmaceutical companies should consider before embarking on the development and launch of a digitally enabled drug delivery device. Our insights are based on hard-won experience and focus on how companies need to adopt a new way of thinking about their users, their product and their project risks.
To receive a copy of the whitepaper, please complete the form below.
